Recombinant proteins | Insulin-like Growth Factor 1 | Therapeutic Agent for Multiple Sclerosis Treatment
Therapeutic Agent for Multiple Sclerosis Treatment
A novel method for treating multiple sclerosis has been developed, providing:

• Symptom relief
• Reduced relapse frequency
• Stimulation of neuronal myelin sheath regeneration

The treatment involves administration of:
1) Somatotropin via injection in specific dosages and regimens
2) Insulin-like Growth Factor 1 (IGF-1) via injection or oral delivery
3) Physiological inducer of somatotropin and/or IGF-1

Conclusion
The developed approaches offer comprehensive disease management, promoting not only symptomatic improvement but also neural tissue restoration.